Miltefosine (impavido): The first oral treatment against leishmaniasis

Miltefosine is a novel antileishmanial drug that has significant selectivity in both in vitro and in vivo models. Clinical efficacy was demonstrated for the treatment of visceral leishmaniasis with the advantage of oral administration over the currently recommended antileishmanial drugs that require...

Full description

Saved in:
Bibliographic Details
Published in:Medical microbiology and immunology 2004-11, Vol.193 (4), p.173-180
Main Authors: SINDERMANN, H, CROFT, S. L, ENGEL, K. R, BOMMER, W, EIBL, H. J, URGER, C, ENGEL, J
Format: Article
Language:English
Subjects:
Administration, Oral
Animals
Antiprotozoal Agents - adverse effects
Antiprotozoal Agents - pharmacokinetics
Antiprotozoal Agents - therapeutic use
Biological and medical sciences
Disease
Drug therapy
Fundamental and applied biological sciences. Psychology
Human protozoal diseases
Humans
Infectious diseases
Leishmania
Leishmaniasis - drug therapy
Leishmaniasis - parasitology
Leshmaniasis
Medical sciences
Medical treatment
Microbiology
Parasitic diseases
Pharmaceuticals
Phosphorylcholine - adverse effects
Phosphorylcholine - analogs & derivatives
Phosphorylcholine - pharmacokinetics
Phosphorylcholine - therapeutic use
Protozoal diseases
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Miltefosine is a novel antileishmanial drug that has significant selectivity in both in vitro and in vivo models. Clinical efficacy was demonstrated for the treatment of visceral leishmaniasis with the advantage of oral administration over the currently recommended antileishmanial drugs that require parenteral administration. Miltefosine produces high cure rates also in patients resistant to the standard antimonial therapy.
ISSN:0300-8584
1432-1831
DOI:10.1007/s00430-003-0201-2